Peter K. Kaiser, M.D.


Peter K. Kaiser, M.D. is a leader in ophthalmic pharmaceutical development with over 15 years of experience in preclinical and clinical development, regulatory submissions, and post-approval sales and marketing. Dr. Kaiser is a principal investigator in over 50 trials evaluating new treatments for AMD, DR, and other retinal disorders, and Study Chairman of 5 major, multi-center, international clinical trials. He has participated in the preparation of regulatory filings and presentations to the FDA for Regeneron, Alimera, and Thrombogenics.

Dr. Kaiser is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR), which is the OCT coordinating center for over 40 multi-center clinical trials. He serves on the scientific advisory boards of Bayer, Novartis, Genentech, GlaxoSmithKline, Allegro, Alcon, Allergan, Regeneron, Bausch and Lomb, Thrombogenics, Alimera, TargeGen, Oraya, ArcticDx, Sequenom, Ophthotech, Kanghong, Heidelberg Engineering, and Carl Zeiss Meditec. He is a National Institute of Health RO1 funded investigator and leads a team involved in the evaluation of vascular biology in age-related macular degeneration and diabetic retinopathy. He has authored six ophthalmology textbooks, and more than 200 peer-reviewed papers. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today, Retinal Physician, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with both Achievement and Senior Achievement Awards. He is the team ophthalmologist for the Cleveland Browns (National Football League) and Cleveland Cavaliers (National Basketball Association).

Dr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute at the Cleveland Clinic Foundation, Cleveland, Ohio where he is the Chaney Family Endowed Chair in Ophthalmology Research and vitreoretinal staff at Cole Eye Institute.